Caribou Biosciences CRBU 深 沪
已收盘 09-19 16:00:00 美东时间
2.07
-0.010
-0.48%
华盛通- 最 高2.22
- 今 开2.18
- 成交量 73.24万股
- 最 低 2.065
- 昨 收 2.08
- 总市值 1.87亿
- 52周最高 8.33
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 1.50
- 委 比 28.37%
- 总股本 9031.45万
- 历史最高 32.645
- 量 比 0.92
- 振 幅 7.45%
- 历史最低 1.50
- 每 手 1
- 风险率 1.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vir Biotechnology names Jason O’Byrne as CFO
Vir Biotechnology (NASDAQ:VIR) said it has appointed Jason O’Byrne as its CFO and executive vice president. The appointment is effective from October 2. Mr. O’Byrne is an industry veteran with over tw...
09-10 20:32
快讯 | Caribou Biosciences-计划任命Ryan Fischesser担任首席会计官，自9月27日业务结束后生效
Caribou Biosciences- Plans to Appoint Ryan Fischesser to Assume Role of Princip...
09-04 04:03
快讯 | Caribou Biosciences Inc - 9月1日，首席财务官杰森·奥拜恩被告知打算辞去职位
Caribou Biosciences Inc - on Sept 1 Jason O'byrne, CFO, Informed of Intent to R...
09-04 04:02
Expert Ratings For Caribou Biosciences
Ratings for Caribou Biosciences (NASDAQ:CRBU) were provided by 4 analysts in th...
09-04 01:00
Caribou Biosciences (CRBU) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Bioscie...
09-03 22:06
快讯 | Caribou Biosciences任命Tina Albertson医学博士为首席医疗官。
Caribou Biosciences Appoints Tina Albertson, Md, Phd, as Chief Medical Officer
08-12 20:00
快讯 | 卡裴生物科技公司：美银全球研究将价格目标从17美元下调至15美元。
Caribou Biosciences Inc : BofA Global Research Cuts Price Objective to $15 From...
08-09 18:55
RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $14 Price Target
RBC Capital analyst Luca Issi reiterates Caribou Biosciences (NASDAQ:CRBU) with a Outperform and maintains $14 price target.
08-07 23:53
快讯 | Caribou Biosciences Inc：Leerink Partners将目标价从10美元下调至9美元
Caribou Biosciences Inc : Leerink Partners Cuts Target Price to $9 From $10
08-07 11:51
Caribou Biosciences Q2 EPS $(0.42) Beats $(0.45) Estimate, Sales $3.46M Beat $3.04M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.45) by 6.67 percent. This is a 12.5 percent increase over losses of $(0.48) per share from
08-07 05:12
